Redhill Biopharma Ltd
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for … Read more
Market Cap & Net Worth: Redhill Biopharma Ltd (RDHL)
Redhill Biopharma Ltd (NASDAQ:RDHL) has a market capitalization of $4.47 Million ($4.47 Million) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #31112 globally and #10239 in its home market, demonstrating a -5.31% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Redhill Biopharma Ltd's stock price $0.88 by its total outstanding shares 5112885 (5.11 Million).
Redhill Biopharma Ltd Market Cap History: 2015 to 2026
Redhill Biopharma Ltd's market capitalization history from 2015 to 2026. Data shows change from $65.85 Billion to $4.47 Million (-60.36% CAGR).
Index Memberships
Redhill Biopharma Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #799 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #2534 of 3165 |
Weight: Redhill Biopharma Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Redhill Biopharma Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Redhill Biopharma Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.95x
Redhill Biopharma Ltd's market cap is 3.95 times its annual revenue
1.02x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $65.85 Billion | $3.00K | -$21.09 Million | 21951319.60x | N/A |
| 2016 | $53.48 Billion | $101.00K | -$29.37 Million | 529512.64x | N/A |
| 2017 | $26.28 Billion | $4.01 Million | -$45.54 Million | 6558.58x | N/A |
| 2018 | $28.38 Billion | $8.36 Million | -$38.82 Million | 3394.32x | N/A |
| 2019 | $31.04 Billion | $6.29 Million | -$42.30 Million | 4933.27x | N/A |
| 2020 | $41.31 Billion | $64.36 Million | -$76.17 Million | 641.90x | N/A |
| 2021 | $13.19 Billion | $85.76 Million | -$97.74 Million | 153.82x | N/A |
| 2022 | $717.34 Million | $61.80 Million | -$71.67 Million | 11.61x | N/A |
| 2023 | $186.62 Million | $6.53 Million | $23.92 Million | 28.58x | 7.80x |
| 2024 | $31.75 Million | $8.04 Million | -$8.27 Million | 3.95x | N/A |
Competitor Companies of RDHL by Market Capitalization
Companies near Redhill Biopharma Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Redhill Biopharma Ltd by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Redhill Biopharma Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Redhill Biopharma Ltd's market cap moved from $65.85 Billion to $ 4.47 Million, with a yearly change of -60.36%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.47 Million | -15.05% |
| 2025 | $5.27 Million | -83.41% |
| 2024 | $31.75 Million | -82.99% |
| 2023 | $186.62 Million | -73.98% |
| 2022 | $717.34 Million | -94.56% |
| 2021 | $13.19 Billion | -68.07% |
| 2020 | $41.31 Billion | +33.11% |
| 2019 | $31.04 Billion | +9.37% |
| 2018 | $28.38 Billion | +7.98% |
| 2017 | $26.28 Billion | -50.86% |
| 2016 | $53.48 Billion | -18.79% |
| 2015 | $65.85 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Redhill Biopharma Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.47 Million USD |
| MoneyControl | $4.47 Million USD |
| MarketWatch | $4.47 Million USD |
| marketcap.company | $4.47 Million USD |
| Reuters | $4.47 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.